Table 2.
Associations between decreased expression of miR-139 and clinicopathological features of breast cancer stratified by ER, PR, or HER2 statuses.
| Decreased miR-139 Expression in Cancer Tissue Relative to Non-Cancer Tissues (T/N Ratio, 2−2.2 = 0.22) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ER | PR | HER2 | ||||||||||
| Positive | Negative | Positive | Negative | Negative | Positive | |||||||
| N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | N (%) | OR (95% CI) | |
| Tumor size (mm3) | ||||||||||||
| ≤20 | 25/55 (45.5) | 1.00 (Ref.) | 23/50 (46.0) | 1.00 (Ref.) | 28/53 (52.8) | 1.00 (Ref.) | 20/51 (39.2) | 1.00 (Ref.) | 30/65 (46.2) | 1.00 (Ref.) | 18/40 (45.0) | 1.00 (Ref.) |
| >20 | 13/26 (50.0) | 1.20 (0.47–3.05) | 36/57 (63.2) | 2.01 (0.92–4.36) | 18/33 (54.5) | 1.07 (0.45–2.56) | 31/50 (62.0) | 2.53 (1.13–5.64) * | 24/45 (53.3) | 1.33 (0.62–2.86) | 25/38 (65.8) | 2.35 (0.94–5.87) |
| Grade | ||||||||||||
| I/II | 27/59 (45.8) | 1.00 (Ref.) | 21/45 (46.7) | 1.00 (Ref.) | 27/55 (49.1) | 1.00 (Ref.) | 21/48 (43.8) | 1.00 (Ref.) | 27/62 (43.5) | 1.00 (Ref.) | 21/42 (50.0) | 1.00 (Ref.) |
| III | 11/22 (50.0) | 1.19 (0.45–3.16) | 38/62 (61.3) | 1.81 (0.83–3.94) | 19/31 (61.3) | 1.64 (0.67–4.02) | 30/53 (56.6) | 1.68 (0.76–3.69) | 27/48 (56.3) | 1.67 (0.78–3.56) | 22/36 (61.1) | 1.57 (0.64–3.88) |
| Stage | ||||||||||||
| I/IIa/IIb | 34/74 (45.9) | 1.00 (Ref.) | 41/84 (48.8) | 1.00 (Ref.) | 38/75 (50.7) | 1.00 (Ref.) | 37/82 (45.1) | 1.00 (Ref.) | 45/96 (46.9) | 1.00 (Ref.) | 30/62 (48.4) | 1.00 (Ref.) |
| Ⅲ/Ⅳ | 4/7 (57.1) | 1.57 (0.33–7.50) | 18/23 (78.3) | 3.78 (1.28–11.11) * | 8/11 (72.7) | 2.60 (0.64–10.55) | 14/19 (73.7) | 3.41 (1.12–10.33) * | 9/14 (64.3) | 2.04 (0.64–6.54) | 13/16 (81.3) | 4.62 (1.20–17.84) * |
| LNM | ||||||||||||
| Negative | 20/44 (45.5) | 1.00 (Ref.) | 25/57 (43.9) | 1.00 (Ref.) | 22/44 (50.0) | 1.00 (Ref.) | 23/57 (40.4) | 1.00 (Ref.) | 29/65 (44.6) | 1.00 (Ref.) | 16/36 (44.4) | 1.00 (Ref.) |
| Positive | 18/37 (48.6) | 1.14 (0.47–2.73) | 34/50 (68.0) | 2.72 (1.23–6.00) * | 24/42 (57.1) | 1.33 (0.57–3.12) | 28/44 (63.6) | 2.59 (1.15–5.82) * | 25/45 (55.6) | 1.55 (0.72–3.33) | 27/42 (64.3) | 2.25 (0.90–5.59) |
LNM, lymph node metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; N/A, data not available. Tumor classification was referred to eighth edition of the American Joint of Committee on Cancer (AJCC) Cancer Staging Manual (2017). ER, PR or HER2 status was classed as negative when fewer than 30% of cells were stained and as positive with more than 30% staining. Ref, reference group. * p < 0.05.